aTYR PHARMA (ATYR) Current Leases (2019 - 2026)
aTYR PHARMA's (ATYR) quarterly Current Leases came in at $596000.0 in Q1 2026, down 19.46% YoY from $740000.0 in Q1 2025, and down 28.71% on a QoQ basis from $836000.0 in Q4 2025.
aTYR PHARMA (ATYR) Current Leases (2019 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 8 years of Current Leases data on file, last reported at $596000.0 in Q1 2026.
- Quarterly Current Leases fell 19.46% year-over-year to $596000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $596000.0 (down 19.46% YoY) and the FY2025 annual result came in at $836000.0, up 17.58% from the prior year.
- Current Leases fell to $596000.0 in Q1 2026, from $836000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.0 million in Q1 2022 to a low of $70000.0 in Q2 2022.
- A 5-year average of $614058.8 and a median of $630000.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases slumped 92.38% — and 2023, when it surged 532.86%.
- Tracing ATYR's Current Leases over 5 years: stood at $630000.0 in 2022, then surged by 31.9% to $831000.0 in 2023, then dropped by 14.44% to $711000.0 in 2024, then rose by 17.58% to $836000.0 in 2025, then dropped by 28.71% to $596000.0 in 2026.
- The last three Current Leases figures came in at $596000.0 (Q1 2026), $836000.0 (Q4 2025), and $630000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 946,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 946,000.00 |
| Mar 31, 2026 | 596,000.00 |
| Dec 31, 2025 | 836,000.00 |
| Sep 30, 2025 | 630,000.00 |
| Jun 30, 2025 | 769,000.00 |
| Mar 31, 2025 | 740,000.00 |
| Dec 31, 2024 | 711,000.00 |
| Sep 30, 2024 | 528,000.00 |
| Jun 30, 2024 | 517,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Dec 31, 2023 | 831,000.00 |
| Sep 30, 2023 | 459,000.00 |
| Jun 30, 2023 | 443,000.00 |
| Mar 31, 2023 | 381,000.00 |
| Dec 31, 2022 | 630,000.00 |
| Sep 30, 2022 | 657,000.00 |
| Jun 30, 2022 | 70,000.00 |
| Mar 31, 2022 | 1.01 Mn |
| Sep 30, 2021 | 949,000.00 |
| Jun 30, 2021 | 919,000.00 |